GSK Trial Data Show Functional Cure Rates For Hepatitis B Treatment

MT Newswires Live05-28

GSK's (GSK) pooled data from two phase 3 clinical trials showed that experimental medicine bepirovirsen achieved a 19% functional cure response rate in individuals with chronic hepatitis B, the drugmaker said Thursday.

The therapy reached a 26% cure rate among patients exhibiting lower baseline viral activity compared with no cures in the placebo group, the company said.

GSK said it anticipates regulatory approvals in Q3.

An exploratory evaluation also indicated nearly half of the participants maintained low surface antigen levels a year after finishing the regimen, GSK said.

The medication demonstrated a tolerable safety profile during the trials, with common side effects including temporary liver enzyme elevation and localized injection site pain, GSK said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638667291?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638667291","market":"sh","top_or_hot":-1,"title":"GSK Trial Data Show Functional Cure Rates For Hepatitis B Treatment","media":"MT Newswires Live","content":"<html><body><p> GSK's (GSK) pooled data from two phase 3 clinical trials showed that experimental medicine bepirovirsen achieved a 19% functional cure response rate in individuals with chronic hepatitis B, the drugmaker said Thursday.</p><p>The therapy reached a 26% cure rate among patients exhibiting lower baseline viral activity compared with no cures in the placebo group, the company said.</p><p>GSK said it anticipates regulatory approvals in Q3.</p><p>An exploratory evaluation also indicated nearly half of the participants maintained low surface antigen levels a year after finishing the regimen, GSK said.</p><p>The medication demonstrated a tolerable safety profile during the trials, with common side effects including temporary liver enzyme elevation and localized injection site pain, GSK said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Trial Data Show Functional Cure Rates For Hepatitis B Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Trial Data Show Functional Cure Rates For Hepatitis B Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> GSK's (GSK) pooled data from two phase 3 clinical trials showed that experimental medicine bepirovirsen achieved a 19% functional cure response rate in individuals with chronic hepatitis B, the drugmaker said Thursday.</p><p>The therapy reached a 26% cure rate among patients exhibiting lower baseline viral activity compared with no cures in the placebo group, the company said.</p><p>GSK said it anticipates regulatory approvals in Q3.</p><p>An exploratory evaluation also indicated nearly half of the participants maintained low surface antigen levels a year after finishing the regimen, GSK said.</p><p>The medication demonstrated a tolerable safety profile during the trials, with common side effects including temporary liver enzyme elevation and localized injection site pain, GSK said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638667291","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638667291","pubTimestamp":1779966331,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"GSK's  pooled data from two phase 3 clinical trials showed that experimental medicine bepirovirsen achieved a 19% functional cure response rate in individuals with chronic hepatitis B, the drugmaker said Thursday.The therapy reached a 26% cure rate among patients exhibiting lower baseline viral activity compared with no cures in the placebo group, the company said.GSK said it anticipates regulatory approvals in Q3.An exploratory evaluation also indicated nearly half of the participants maintained low surface antigen levels a year after finishing the regimen, GSK said.The medication demonstrated a tolerable safety profile during the trials, with common side effects including temporary liver enzyme elevation and localized injection site pain, GSK said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克","BK4532":"文艺复兴科技持仓","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSKH":"GSK plc ADRhedged","GSK.UK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"GSK试验数据显示乙肝治疗的功能性治愈率","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK":1.5,"GSK.UK":0.6},"content_text":"GSK's (GSK) pooled data from two phase 3 clinical trials showed that experimental medicine bepirovirsen achieved a 19% functional cure response rate in individuals with chronic hepatitis B, the drugmaker said Thursday.The therapy reached a 26% cure rate among patients exhibiting lower baseline viral activity compared with no cures in the placebo group, the company said.GSK said it anticipates regulatory approvals in Q3.An exploratory evaluation also indicated nearly half of the participants maintained low surface antigen levels a year after finishing the regimen, GSK said.The medication demonstrated a tolerable safety profile during the trials, with common side effects including temporary liver enzyme elevation and localized injection site pain, GSK said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638667291","isCrawlerRequest":true}